Sitagliptin 25 mg (Sitagliptin Hydrochloride Monohydrate)
Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoo Pharmaceutical Co., Ltd.
MFDS item code 202101001 · Approved 2021.02.02
This product's status changed to Expired on 2026.02.02. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. It can be administered as monotherapy, and for patients who have not previously received diabetes pharmacotherapy and find sufficient glycemic control difficult with monotherapy, it is administered in combination with metformin. Additionally, when glycemic control is difficult with monotherapy of sulfonylureas, metformin, thiazolidinediones, or insulin, this medication is administered to assist in glycemic management. Even in cases involving multiple medications, adding this medication can be expected to enhance glycemic control effects. This medication is also useful in improving glycemic control in complex treatment scenarios.
This medication is administered at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. It may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). Patients with renal impairment As dosage adjustment is required based on renal function, assessment of renal function is recommended before starting this medication and periodically thereafter. 1. No dosage adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. In patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This medication may be administered regardless of the timing of dialysis.
This medication may cause allergic reactions, so if symptoms such as skin rash or difficulty breathing occur, discontinue use immediately and consult a physician. During the use of this medication, if symptoms of pancreatitis such as abdominal pain, nausea, or vomiting occur, inform medical personnel immediately. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Patients with impaired renal function need dosage adjustments, so regular kidney function tests are required. When taken with other hypoglycemic agents, especially insulin or sulfonylureas, the risk of hypoglycemia may increase, so blood glucose levels should be monitored closely. If severe joint pain or skin blisters appear during treatment with this medication, inform a physician immediately, and discontinue use if necessary. Pregnant or lactating women should not take this medication, and safety in children under 18 has not been established. Elderly patients may have reduced renal function, necessitating dosage adjustments and kidney function testing. In cases of overdose, seek proper treatment at a medical facility immediately, as this medication can be partially removed by hemodialysis. This medication has minimal interactions with other drugs, but it is important to inform medical personnel when taking certain medications.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent air or moisture infiltration. It should be kept at room temperature between 1 to 30 degrees Celsius, away from extreme heat or cold.
Pink, round, biconvex film-coated tablets
28 tablets/box [14 tablets/PTP x 2]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoo Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.